Hemostemix Inc. (CVE:HEM – Get Free Report)’s share price rose 34.5% during trading on Thursday . The company traded as high as C$0.20 and last traded at C$0.20. Approximately 143,687 shares traded hands during trading, a decline of 72% from the average daily volume of 515,150 shares. The stock had previously closed at C$0.15.
Hemostemix Trading Down 7.9 %
The company has a debt-to-equity ratio of -55.07, a current ratio of 0.04 and a quick ratio of 0.48. The business has a 50 day moving average of C$0.20 and a 200 day moving average of C$0.12. The firm has a market capitalization of C$25.50 million, a price-to-earnings ratio of -5.10 and a beta of 0.20.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Further Reading
- Five stocks we like better than Hemostemix
- What is the Australian Securities Exchange (ASX)
- Unity Stock: Is a True Turnaround Finally Taking Shape?
- Find and Profitably Trade Stocks at 52-Week Lows
- DuPont’s Electronics Spinoff: The Start of Something Big
- How Investors Can Find the Best Cheap Dividend Stocks
- The Trade Desk Crashes on Earnings, But Growth Catalysts Persist
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
